On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1987-10

AUTHORS

E. Petru, D. Schmähl

ABSTRACT

We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients. The overall response rates in patients treated with these hormonal single agents at various dose levels ranged from 31%–42%. When only estrogen receptor-positive patients were considered, the response rates lay between 41% and 54% in groups which were treated with the antiestrogenic agents tamoxifen or aminoglutethimide. The duration of remission was 12 months for tamoxifen- and aminoglutethimide-treated women, whereas medroxy-progesterone acetate effected remissions lasting from 6–16 months. The overall mean survival from start of therapy in tamoxifen- and aminoglutethimide-treated groups was 20 months, whereas information concerning this therapeutic parameter was available only in a minority of medroxyprogesterone acetate-treated groups. With respect to the response by site of metastatic lesions, all three agents caused a significantly higher degree of remissions in the soft tissue as compared to visceral disease. More... »

PAGES

959-966

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01717830

DOI

http://dx.doi.org/10.1007/bf01717830

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035184646

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2963170


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0304", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medicinal and Biomolecular Chemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aminoglutethimide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medroxyprogesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medroxyprogesterone Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr Toxikologie und Chemotherapie, Deutsches Krebsforschungszentrum, Heidelberg", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institut f\u00fcr Toxikologie und Chemotherapie, Deutsches Krebsforschungszentrum, Heidelberg"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petru", 
        "givenName": "E.", 
        "id": "sg:person.01063471533.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063471533.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr Toxikologie und Chemotherapie, Deutsches Krebsforschungszentrum, Heidelberg", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institut f\u00fcr Toxikologie und Chemotherapie, Deutsches Krebsforschungszentrum, Heidelberg"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schm\u00e4hl", 
        "givenName": "D.", 
        "id": "sg:person.0105462430.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0105462430.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00258291", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039777763", 
          "https://doi.org/10.1007/bf00258291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1971.33", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033932369", 
          "https://doi.org/10.1038/bjc.1971.33"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01486845", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032922941", 
          "https://doi.org/10.1007/bf01486845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01805860", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041216952", 
          "https://doi.org/10.1007/bf01805860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1983.232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013148738", 
          "https://doi.org/10.1038/bjc.1983.232"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00258132", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022711048", 
          "https://doi.org/10.1007/bf00258132"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01805882", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015794556", 
          "https://doi.org/10.1007/bf01805882"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00254419", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011258136", 
          "https://doi.org/10.1007/bf00254419"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1987-10", 
    "datePublishedReg": "1987-10-01", 
    "description": "We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients. The overall response rates in patients treated with these hormonal single agents at various dose levels ranged from 31%\u201342%. When only estrogen receptor-positive patients were considered, the response rates lay between 41% and 54% in groups which were treated with the antiestrogenic agents tamoxifen or aminoglutethimide. The duration of remission was 12 months for tamoxifen- and aminoglutethimide-treated women, whereas medroxy-progesterone acetate effected remissions lasting from 6\u201316 months. The overall mean survival from start of therapy in tamoxifen- and aminoglutethimide-treated groups was 20 months, whereas information concerning this therapeutic parameter was available only in a minority of medroxyprogesterone acetate-treated groups. With respect to the response by site of metastatic lesions, all three agents caused a significantly higher degree of remissions in the soft tissue as compared to visceral disease.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf01717830", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1057918", 
        "issn": [
          "0946-2716", 
          "1432-1440"
        ], 
        "name": "Journal of Molecular Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "20", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "65"
      }
    ], 
    "keywords": [
      "hormone monotherapy", 
      "medroxyprogesterone acetate", 
      "breast cancer", 
      "response rate", 
      "estrogen receptor-positive patients", 
      "receptor-positive patients", 
      "antiestrogenic agent tamoxifen", 
      "start of therapy", 
      "advanced breast cancer", 
      "metastatic breast cancer", 
      "duration of remission", 
      "overall response rate", 
      "overall mean survival", 
      "visceral disease", 
      "metastatic lesions", 
      "clinical studies", 
      "mean survival", 
      "single agent", 
      "dose levels", 
      "tamoxifen", 
      "therapeutic efficacy", 
      "therapeutic parameters", 
      "remission", 
      "patients", 
      "soft tissue", 
      "monotherapy", 
      "months", 
      "cancer", 
      "aminoglutethimide", 
      "group", 
      "medroxyprogesterone", 
      "therapy", 
      "lesions", 
      "agents", 
      "disease", 
      "women", 
      "efficacy", 
      "survival", 
      "tissue", 
      "duration", 
      "rate", 
      "acetate", 
      "response", 
      "levels", 
      "minority", 
      "start", 
      "study", 
      "role", 
      "high degree", 
      "sites", 
      "degree", 
      "results", 
      "information", 
      "respect", 
      "parameters"
    ], 
    "name": "On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer", 
    "pagination": "959-966", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035184646"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01717830"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2963170"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01717830", 
      "https://app.dimensions.ai/details/publication/pub.1035184646"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_188.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf01717830"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01717830'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01717830'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01717830'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01717830'


 

This table displays all metadata directly associated to this object as RDF triples.

195 TRIPLES      21 PREDICATES      99 URIs      83 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01717830 schema:about N0a5714256868485fbfd58569cb5e5c4d
2 N4c4f63de1261410a9a1da3d102cd5d7c
3 N646d68386606471ba92ec0cff4c55b0d
4 N7c94015ac3b74d52a1a9dff0f69ad1c0
5 N9a67a95924a9428db8e3354c27eaf898
6 Nb333f192e3564162b88b7abf43b652f7
7 Nc47da2a6d57847518b6062af9115e436
8 Nd799a895fd244ac4b1bc6cae8e255d0d
9 Ndd5274fde06a4836ab53bcd6bec758e9
10 Nf40400fa511748a9a047e42f2aea2927
11 anzsrc-for:03
12 anzsrc-for:0304
13 schema:author N7db6d678b6714941a426c6f702d1d6c7
14 schema:citation sg:pub.10.1007/bf00254419
15 sg:pub.10.1007/bf00258132
16 sg:pub.10.1007/bf00258291
17 sg:pub.10.1007/bf01486845
18 sg:pub.10.1007/bf01805860
19 sg:pub.10.1007/bf01805882
20 sg:pub.10.1038/bjc.1971.33
21 sg:pub.10.1038/bjc.1983.232
22 schema:datePublished 1987-10
23 schema:datePublishedReg 1987-10-01
24 schema:description We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients. The overall response rates in patients treated with these hormonal single agents at various dose levels ranged from 31%–42%. When only estrogen receptor-positive patients were considered, the response rates lay between 41% and 54% in groups which were treated with the antiestrogenic agents tamoxifen or aminoglutethimide. The duration of remission was 12 months for tamoxifen- and aminoglutethimide-treated women, whereas medroxy-progesterone acetate effected remissions lasting from 6–16 months. The overall mean survival from start of therapy in tamoxifen- and aminoglutethimide-treated groups was 20 months, whereas information concerning this therapeutic parameter was available only in a minority of medroxyprogesterone acetate-treated groups. With respect to the response by site of metastatic lesions, all three agents caused a significantly higher degree of remissions in the soft tissue as compared to visceral disease.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf Naf983327400a40e09646a5e1c460674a
28 Nedc9da136c894a4590d303b3598c8e45
29 sg:journal.1057918
30 schema:keywords acetate
31 advanced breast cancer
32 agents
33 aminoglutethimide
34 antiestrogenic agent tamoxifen
35 breast cancer
36 cancer
37 clinical studies
38 degree
39 disease
40 dose levels
41 duration
42 duration of remission
43 efficacy
44 estrogen receptor-positive patients
45 group
46 high degree
47 hormone monotherapy
48 information
49 lesions
50 levels
51 mean survival
52 medroxyprogesterone
53 medroxyprogesterone acetate
54 metastatic breast cancer
55 metastatic lesions
56 minority
57 monotherapy
58 months
59 overall mean survival
60 overall response rate
61 parameters
62 patients
63 rate
64 receptor-positive patients
65 remission
66 respect
67 response
68 response rate
69 results
70 role
71 single agent
72 sites
73 soft tissue
74 start
75 start of therapy
76 study
77 survival
78 tamoxifen
79 therapeutic efficacy
80 therapeutic parameters
81 therapy
82 tissue
83 visceral disease
84 women
85 schema:name On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer
86 schema:pagination 959-966
87 schema:productId N017c044b19b84be9a8a928bc470a06ac
88 N1000cadce517413fba13b04c1aeba1f1
89 N1b8550bd4468404dbc0670a047e76851
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035184646
91 https://doi.org/10.1007/bf01717830
92 schema:sdDatePublished 2022-12-01T06:19
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Ndbe0bfaf95a7424791721ce22ffa5ed0
95 schema:url https://doi.org/10.1007/bf01717830
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N017c044b19b84be9a8a928bc470a06ac schema:name dimensions_id
100 schema:value pub.1035184646
101 rdf:type schema:PropertyValue
102 N0a5714256868485fbfd58569cb5e5c4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Medroxyprogesterone Acetate
104 rdf:type schema:DefinedTerm
105 N1000cadce517413fba13b04c1aeba1f1 schema:name doi
106 schema:value 10.1007/bf01717830
107 rdf:type schema:PropertyValue
108 N161ae82120c54fa68011d80b66996618 rdf:first sg:person.0105462430.55
109 rdf:rest rdf:nil
110 N1b8550bd4468404dbc0670a047e76851 schema:name pubmed_id
111 schema:value 2963170
112 rdf:type schema:PropertyValue
113 N4c4f63de1261410a9a1da3d102cd5d7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Antineoplastic Agents
115 rdf:type schema:DefinedTerm
116 N646d68386606471ba92ec0cff4c55b0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Follow-Up Studies
118 rdf:type schema:DefinedTerm
119 N7c94015ac3b74d52a1a9dff0f69ad1c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Dose-Response Relationship, Drug
121 rdf:type schema:DefinedTerm
122 N7db6d678b6714941a426c6f702d1d6c7 rdf:first sg:person.01063471533.53
123 rdf:rest N161ae82120c54fa68011d80b66996618
124 N9a67a95924a9428db8e3354c27eaf898 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Humans
126 rdf:type schema:DefinedTerm
127 Naf983327400a40e09646a5e1c460674a schema:issueNumber 20
128 rdf:type schema:PublicationIssue
129 Nb333f192e3564162b88b7abf43b652f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Aminoglutethimide
131 rdf:type schema:DefinedTerm
132 Nc47da2a6d57847518b6062af9115e436 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Combined Modality Therapy
134 rdf:type schema:DefinedTerm
135 Nd799a895fd244ac4b1bc6cae8e255d0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Medroxyprogesterone
137 rdf:type schema:DefinedTerm
138 Ndbe0bfaf95a7424791721ce22ffa5ed0 schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 Ndd5274fde06a4836ab53bcd6bec758e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Breast Neoplasms
142 rdf:type schema:DefinedTerm
143 Nedc9da136c894a4590d303b3598c8e45 schema:volumeNumber 65
144 rdf:type schema:PublicationVolume
145 Nf40400fa511748a9a047e42f2aea2927 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Tamoxifen
147 rdf:type schema:DefinedTerm
148 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
149 schema:name Chemical Sciences
150 rdf:type schema:DefinedTerm
151 anzsrc-for:0304 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medicinal and Biomolecular Chemistry
153 rdf:type schema:DefinedTerm
154 sg:journal.1057918 schema:issn 0946-2716
155 1432-1440
156 schema:name Journal of Molecular Medicine
157 schema:publisher Springer Nature
158 rdf:type schema:Periodical
159 sg:person.0105462430.55 schema:affiliation grid-institutes:grid.7497.d
160 schema:familyName Schmähl
161 schema:givenName D.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0105462430.55
163 rdf:type schema:Person
164 sg:person.01063471533.53 schema:affiliation grid-institutes:grid.7497.d
165 schema:familyName Petru
166 schema:givenName E.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063471533.53
168 rdf:type schema:Person
169 sg:pub.10.1007/bf00254419 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011258136
170 https://doi.org/10.1007/bf00254419
171 rdf:type schema:CreativeWork
172 sg:pub.10.1007/bf00258132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022711048
173 https://doi.org/10.1007/bf00258132
174 rdf:type schema:CreativeWork
175 sg:pub.10.1007/bf00258291 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039777763
176 https://doi.org/10.1007/bf00258291
177 rdf:type schema:CreativeWork
178 sg:pub.10.1007/bf01486845 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032922941
179 https://doi.org/10.1007/bf01486845
180 rdf:type schema:CreativeWork
181 sg:pub.10.1007/bf01805860 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041216952
182 https://doi.org/10.1007/bf01805860
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/bf01805882 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015794556
185 https://doi.org/10.1007/bf01805882
186 rdf:type schema:CreativeWork
187 sg:pub.10.1038/bjc.1971.33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033932369
188 https://doi.org/10.1038/bjc.1971.33
189 rdf:type schema:CreativeWork
190 sg:pub.10.1038/bjc.1983.232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013148738
191 https://doi.org/10.1038/bjc.1983.232
192 rdf:type schema:CreativeWork
193 grid-institutes:grid.7497.d schema:alternateName Institut für Toxikologie und Chemotherapie, Deutsches Krebsforschungszentrum, Heidelberg
194 schema:name Institut für Toxikologie und Chemotherapie, Deutsches Krebsforschungszentrum, Heidelberg
195 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...